{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-108591","form_type":"8-K","ticker":"SRRK","cik":"0001727196","company_name":"Scholar Rock Holding Corp","filed_at":"2023-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.204436+00:00","generated_at":"2026-06-10T01:44:04.208928+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Scholar Rock advances SRK-439 for obesity towards 2025 IND; Phase 2 apitegromab trial in 2024 with mid-2025 data","bullets":["Plans to file IND for SRK-439, a novel myostatin inhibitor for obesity, in 2025.","Initiating Phase 2 proof-of-concept trial of apitegromab in combination with GLP-1 RA in obesity in 2024; data expected mid-2025.","Preclinical data show SRK-439 combined with GLP-1 RA reversed lean mass loss and enhanced fat mass loss in diet-induced obese mice.","Pivotal Phase 3 SAPPHIRE trial of apitegromab in SMA fully enrolled; topline data expected Q4 2024.","Leverages selective myostatin inhibition platform; apitegromab already well-tolerated in SMA."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-108591","json":"https://secwatch.observer/filing/0001104659-23-108591.json","markdown":"https://secwatch.observer/filing/0001104659-23-108591.md","text":"https://secwatch.observer/filing/0001104659-23-108591.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1727196/000110465923108591/0001104659-23-108591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1727196/000110465923108591/tm2328106d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T01:44:04.208928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}